Also called: Lys-Pro-Val, Lysine-Proline-Valine, KPV tripeptide
KPV is a very small protein building block, made of just three tiny pieces joined together. It is a copy of the last part of a bigger body chemical that helps control swelling. Scientists first found it in the body's natural messengers that affect skin color and healing. People who use it are usually looking for help with skin problems, gut troubles, or body-wide swelling.
KPV's main job seems to be calming things down. It works by entering cells and turning down the signals that cause redness, heat, and swelling. Research in labs and animals shows it can soothe irritated skin and calm an upset gut lining. It is being studied as a cream for skin and as a swallowed or injected compound for gut health.
Human research is still limited, so much of what people say about KPV comes from animal studies and personal stories. It is not an approved medicine in the United States. Recently, a government advisory group voted to suggest it for a list that would let special pharmacies prepare it, but no final rule has been made yet. Anyone thinking about using it should talk to a doctor and be careful about where it comes from, since unregulated sellers do not have to prove their products are pure or safe.
Building Blocks
KPV is one of the building blocks in this blend or stack people actually buy:
On July 23, 2026, PCAC voted 8–6–1 to recommend adding KPV to the Section 503A Bulks List. The vote is advisory — FDA is not bound by it and must complete formal rulemaking before KPV could be lawfully compounded under 503A. KPV is not currently on the 503A Bulks List, remains an unapproved new drug, and may not be lawfully compounded by traditional 503A pharmacies in the interim.
Benefits
The main themes across 37 research studies, in plain language.
Research suggests KPV may significantly reduce intestinal inflammation and support the management of inflammatory bowel conditions like colitis.
Research indicates KPV may utilize the PepT1 transporter to target the gut, helping to restore tight junctions and protect the intestinal lining.
Evidence suggests KPV may accelerate wound closure, support collagen synthesis, and enhance the repair of skin and mucosal tissues.
Studies indicate that KPV may inhibit key inflammatory pathways (NF-κB, MAPK) and lower pro-inflammatory cytokines throughout the body.
Research suggests KPV may help regulate immune responses and reduce autoimmune activity without causing broad immunosuppression.
Studies suggest KPV may possess antimicrobial properties that help combat specific bacteria and fungi, such as Staphylococcus aureus.
Research suggests KPV may help lower oxidative stress markers and protect cells from free radical damage.
Preliminary research indicates potential for protecting the brain and reducing neuroinflammation following injury or in states of brain fog.
Research points to potential benefits for inflammatory skin issues, including psoriasis, eczema, and redness, without causing pigmentation changes.
Animal studies suggest KPV may help reduce the risk of tumor development specifically associated with chronic colitis.
See where KPV fits — the most-used combinations, dosing notes from the research, and what to check before you buy.
No spam. Unsubscribe anytime.
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Evidence
Every claim above traces back to a source you can check — here are 4 of them.
Structural modification of the tripeptide KPV by reductive "glycoalkylation" of the lysine residue.
kpv
A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon
KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy
Timeline
Key moments in KPV’s research and regulatory timeline — sourced and dated.
News
Dated, sourced reporting that mentions KPV.
The FDA has announced the agenda for the July 2026 meeting of the Pharmacy Compounding Advisory Committee (PCAC). The committee will review specific bulk drug substances, including BPC-157 and KPV, for potential inclusion on the 503A Bulks List. This meeting represents a critical regulatory step toward determining the legal status of these peptides for pharmacy compounding.
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended adding six of seven reviewed peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax) to the Section 503A Bulks List and rejected Emideltide/DSIP. The vote is advisory only — not a final FDA decision and not legal authorization to compound. FDA must still complete formal notice-and-comment rulemaking (typically 12–24 months) before any change in legal status.
Wondering how KPV pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Explore by goal
Compare
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.